URGN 241220 12.50C (URGN241220C12500) Stock Options, News & Quotes

US OptionsDetailed Quotes

URGN241220C12500

Watchlist

0.75
+0.20+36.36%

15min DelayClose Nov 25 16:00 ET

0.75High0.70Low

Intraday

5D
Daily

News

Further Weakness as UroGen Pharma (NASDAQ:URGN) Drops 13% This Week, Taking Five-year Losses to 64%
Simply Wall StNov 18 06:14 ET
UroGen Pharma Ltd. (URGN) Q3 2024 Earnings Call Transcript Summary
moomoo AINov 6 17:21 ET · Conference Call
UroGen Pharma Ltd. (URGN) Q3 2024 Earnings Call Transcript
Earnings Call TranscriptsNov 6 17:12 ET
TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Announces Target Price $35
Moomoo NewsNov 6 15:31 ET · Ratings
Express News | EF Hutton Maintains Buy on UroGen Pharma, Maintains $25 Price Target
BenzingaNov 6 11:19 ET
UroGen Pharma Ltd | 10-Q: Q3 2024 Earnings Report
SECNov 6 08:07 ET · Announcements

Comments

Stock_Drift

Oct 15 15:37

$UroGen Pharma Ltd (URGN.US)$

MARKET-TEST-DUMMY

Jun 15 16:25

Will it keep the rise

$UroGen Pharma Ltd (URGN.US)$

TrendTrader

Jun 13 11:57

Curling. Watching for retest of hod

$UroGen Pharma Ltd (URGN.US)$

TrendTrader

Jun 13 10:19

Looking for 20-25+

$UroGen Pharma Ltd (URGN.US)$

Jaguar8

Jun 13 10:17

Reason for Price Rally

$UroGen Pharma Ltd (URGN.US)$
UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
• Kaplan-Meier Estimate of Duration of Response at 12 Months in Patients Who Achieved a Complete Response at Three Months was 82.3% (95% CI, 75.9%, 87.1%)
• Side Effect Profile Consistent with Previous Clinical Trials of UGN-102
• UroGen will Host a Virt...